Acquired hemophilia A: a review of recent data and new therapeutic options

作者：Franchini Massimo^*; Vaglio Stefania; Marano Giuseppe; Mengoli Carlo; Gentili Sara; Pupella Simonetta; Liumbruno Giancarlo Maria

来源：Hematology, 2017, 22(9): 514-520.

DOI：10.1080/10245332.2017.1319115

• Acquired hemophilia A
• factor VIII
• bleeding
• eradication therapy

Objectives: Acquired hemophilia A (AHA) is a rare, but potentially life-threatening, bleeding disorder caused by an autoantibody against factor VIII that interferes with its coagulant function.
Methods: We performed a narrative review focusing on the diagnostic aspects of AHA and on the current treatment strategies with particular regard to new data and therapeutic developments.
Results: The management of this severe hemorrhagic disorder is based on the control of bleeding with the use of bypassing agents and on the utilization of a variety of immunosuppressant agents with the goal of eliminating the autoantibody permanently.
Conclusion: The optimal management of AHA should be multidisciplinary and requires a close collaboration between physicians from various specialties.

• 出版日期2017